Home > Result Summaries: Compounds > fluticasone propionate/salmeterol > Result Summary for SAS10003

Result Summary for SAS10003

Result Summary

Protocol ID:	SAS10003
Clinical Study ID:	SAS10003
Official Title:	A Double-Blind, Placebo-Controlled Four Way Crossover Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Fluticasone Propionate and Salmeterol With Increasing Dose Strengths of the Fluticasone Propionate/Salmeterol/HFA134A MDI Combination Product
Phase:	Phase 1
Study Indications or Diseases:	Respiratory Disorders
Generic Name:	fluticasone propionate/salmeterol
Trade/Product Name:	advair;seretide
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Abstract: Dose proportionality and in vivo performa strengths (50125, 125125, and 250125 propionate/salmeterol metered-dose inhalers in healthy subjects. SMS Andrews, RL Kunka, Y Yin, Karen Callahan, M York, PT Daley-Yates. 58th Annual Meeting of the American Academy of Allergy, Asthma and Immunology 3/1/2002 New York NY Kunka RL, Andrews SMS, Yin Y, Callejas S, York M, and Daley-Yates PT, “Dose Proportionality and In Vivo Performance for Three Strengths (50/25, 125/25, and 250/25) of Fluticasone Propionate/Salmeterol Metered-Dose Inhalers in Healthy Subjects”, Presented at American College of Allergy, Asthma and Immunology (ACAAI), New York, March 2002